All News

Stuck in the pharmacy during the New Year’s Eve festivities? This Pharmacy Times countdown has everything you need for celebrating the holiday with your pharmacy team.

Deeb Eid, PharmD, is creator of the Pharmacy Universe podcast on Spreaker. An associate professor and experiential coordinator at Ferris State University College of Pharmacy in Grand Rapids, MI, Eid speaks with pharmacy industry guests to educate and engage listeners about the profession.

Individuals with HIV have more QT interval variability than those without the disease, which may lead to the increased risk of sudden cardiac death.

Researchers may have found a way to stop the driving force at a molecular level behind acute lymphoblastic leukemia.

Ashley M. Rogers, PharmD, BCPS, has been named the 2019 Distinguished Young Pharmacist of the Year in Massachusetts.

Officials with the FDA have approved Eisai’s lemborexant (Dayvigo) 5 mg and 10 mg for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Officials with the FDA have approved Intra-Cellular Therapies’ lumateperone (Caplyta) for the treatment of schizophrenia in adults, according to the company.

What classic Christmas movie character fits best with your pharmacy profession?

Patients with epilepsy treated with perampanel during routine clinical care had favorable retention rates and sustained efficacy.

The applications for the first generics of apixaban (Eliquis, Bristol-Meyers Squibb) tablets were approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation

Ubrogepant is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved by the agency for the acute treatment of migraine.

Baclofen use, particularly at higher doses, may result in an increased risk of encephalopathy among patients with chronic kidney disease.

Officials with the FDA have granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi-Sankyo) for the treatment of adults with unresectable or metastatic HER2-positive breast cancer that have received 2 or more prior anti-HER2-based regimens in the metastatic setting.